



PRESS RELEASE, 4 August 2003

Invitation to participate in additional conference call regarding Perbio Science AB's Interim Report January – June 2003

The presentation and Q&A session regarding Perbio Science AB's Interim Report January – June 2003 was held in Stockholm on August 1. We are grateful for the large number of participants that visited us in person and also listened in via telephone and web cast. However, due to technical problems not all questions from the remote participants came through to us. We apologise for this and would like to give you an opportunity to attend a new telephone conference with opportunities to ask questions.

Conference call will be held on Thursday August 7 at 15.00 CET (9.00 am EST)

CEO Leland Foster and CFO Claes Wentzel will be available to answer additional questions relating to the Interim Report January – June 2003.

To participate in the conference call please dial +46 8 727 77 51

You are welcome to download the presentation slides in advance from our website www.perbio.com.

You can also access a recording of the presentation held on August 1 at www.financialhearings.com

Further information

**Leland G Foster, CEO
or Claes Wentzel, Vice President & CFO**

**phone +1 435 757 6432
phone: +46 42 26 90 92 or +46 70 862 01 22**

Perbio Science AB (publ) is a listed Swedish biotech company with research institutions, pharmaceutical companies and diagnostic companies as its customers. The USA accounts for the bulk of its business. Perbio Science supplies products, systems and services for the study and production of proteins and develops products in the Bioresearch, Cell Culture and Medical Device fields. The group has 1,353 employees and offices in Sweden, the USA and a number of other countries. Its head office is in Helsingborg, Sweden.

More information regarding Perbio Science can be found at www.perbio.com